Dichiarazione ICRP sulle reazioni tissutali ed effetti immediati e tardivi delle radiazioni nei tessuti e negli organi normali - Dosi soglia per le reazioni tissutali nell’ambito della radioprotezione

La pubblicazione ICRP 118 riesamina gli effetti precoci e tardivi delle radiazioni ionizzanti nei diversi organi ed apparati e fornisce stime aggiornate sulle dosi soglia per l'induzione delle numerose reazioni tissutali analizzate. In particolare, a seguito dei progressi nelle conoscenze radiobiologiche e cliniche, pubblicati in numerosi testi specialistici, vengono dettagliatamente presentate le evidenze che hanno condotto alle modificazioni, rispetto alle Raccomandazioni ICRP 103/2007, nella individuazione delle dosi soglia per la induzione della cataratta e delle patologie del sistema circolatorio da parte delle radiazioni ionizzanti. A queste rilevanti considerazioni si affiancano gli approfonditi aggiornamenti sulle conoscenze radiobiologiche e cliniche e le integrazioni delle dosi soglia, individuate in modo più articolato rispetto alle precedenti pubblicazioni, per tutte le altre reazioni tissutali, che rendono questo documento un indispensabile strumento di lavoro e di analisi per tutti coloro che si occupano di radioprotezione, con particolare riferimento agli specialisti di radioprotezione medica. La traduzione in italiano dell’intero testo vuole facilitare la diffusione delle peculiari informazioni contenute nella pubblicazione e motivare una sempre più approfondita ricerca in questo settore che indubbiamente contribuisce a ridurre i rischi derivanti dall’esposizione alle radiazioni ionizzanti. La realizzazione della versione italiana di questa pubblicazione ha richiesto un notevole impegno qualitativo e quantitativo ed è stata possibile per il considerevole e qualificante contributo dei medici dell’AIRM e dei membri del Comitato Internazionale dell'AIRP. A tutti coloro che hanno collaborato alla sua traduzione, revisione e pubblicazione con notevole spirito di sacrificio, è rivolto l'apprezzamento e la riconoscenza delle nostre Associazioni, che riuniscono gli operatori attivi nei vari settori di interesse della radioprotezione

Italy: Operational Problems Implementing the Euratom Directives.

The Italian National regulations on the peaceful use of nuclear energy have not been changed during a 31-year-period since 1964. In 1995, the legislative decree No. 230, dated 17th March 1995, has been issued, in which all the Euratom directives relevant at that time and part of the new EU basic safety standards have been acknowledged by the legislator. The represented a remarkable improvement for the radioprotection in Italy leading it, perhaps for the first time, to the forefront with respect to other European Partners.However, presently thr ministerial decrees, useful and necessary in order to accomplish the full objectives of the legislative decree 230/95, have not been issued yet. Starting from this situation, the impact of the new Euratom Directive with regard to the legislative decree 230/95 is pointed out here.JRC-Joint Research Centr

A View from Ispra: How Unifying are the Euratom Directives?

Since 1992 the European Market comprises an area without internal frontiers, in which the free movement of goods and persons is established. Within this context, operators are sometimes called on to provide services involving the use of radiological equipment or radioactive substances in member states other than in which their organisation is located. The laudable effort to prepare European directives that are always up-to-date and clear is evident to every operator and expert in the field. But it is still a long way from offering to the nuclear operators the possibility to operate in all EU States as easily as in one's own country. This is eximplified for various fields of radiation protection in the following passages.JRC-Joint Research Centr

Impianti Nucleari in Europa e Decommissioning. Part II. Germania.

Abstract not availableJRC.B-Resource Managemen

Radiation Protection organization in radioactive waste management at the Joint Research Centre of Ispra

The Joint Research Centre of Ispra, one of the research Sites belonging to the European Commission, Directorate General JRC, was created in the late ¿50s, in order to steer European research on nuclear industry. It hosts numerous nuclear facilities, some of which are maintained in operation, while others were shutdown in past years, namely: two research nuclear reactors, hot cells facilities, radiochemical laboratories, one Cyclotron (still in operation), facilities for studies on fissile material (in operation), and some facilities for the treatment and storage of liquid and solid waste (in operation). The JRC accounts for 16 nuclear licences, 14 Controlled Zones and 12 main Surveilled Zones, on its Ispra Site. This paper will discuss the organization which has been developed, during the years, and put in place to guarantee highest safety levels in all radiation work activities at the JRC-Ispra, with an emphasis on radioactive waste management. The present strategy for waste management at the JRC will be briefly discussed, and its major facilities will be introduced in detail. Processes discussed will include: 1. Decontamination of surfaces via Abrasive Blasting Unit (ABU) 2. Measurements of materials in the Material Clearance Facility (MCF) 3. Radiological characterisation of waste (active and passive, XDRS and WCF) 4. Radioactive transports and accountancy 5. Interim storage at the JRCJRC.C.1-Nuclear Decommissionin

Impianti Nucleari in Europa e Decommissioning. Parte I. Inghilterra.

Abstract not availableJRC.C-Ispra Site Directorate (Ispra

Internal and External Dosimetry organization in the Joint Research Centre of Ispra

Abstract The Joint Research Centre of Ispra, one of the research Sites belonging to the European Commission, Directorate General JRC, was created in the late ¿50s, in order to steer European research on nuclear industry. It hosts numerous nuclear facilities, some of which are maintained in operation, while others were shutdown in past years, namely: two research nuclear reactors, hot cells facilities, radiochemical laboratories, one Cyclotron (still in operation), facilities for studies on fissile material (in operation), and some facilities for the treatment and storage of liquid and solid waste (in operation). The JRC accounts for 16 nuclear licences, 14 Controlled Zones and 12 main Surveilled Zones, on its Ispra Site. The Radiation Protection Sector employs the services of some internal laboratories for the assessment of external and internal doses: the ¿Dosimetry¿ Laboratory (for personal and ambient TLDs), the Whole Body Count Laboratory, the Radiotoxicological Laboratory (for analyses on excreta), the Radiation Protection Sector itself (for ambient dose and contamination reporting, and electronic personal dosimeters readings). Some of these Services are open also to the external market, and JRC-Ispra is among the few being able to provide, in Italy, either for internal and external dosimetric services to Customers. The paper will discuss the organization and the structure of the Dosimetry and the Whole Body Count Laboratories, and their functions in the management of daily Radiation Protection tasks at the JRC. Moreover, in order to follow-up and control Personnel radiation doses, the Radiation Protection Sector has developed and put in place, in 2007, the ¿Unified Dosimetry System¿, a wide and flexible database centralizing all dosimetric data and making them on-line available to JRC Radiation Protection experts and to the JRC Qualified Expert.JRC.C.1-Nuclear Decommissionin

Misure di Radon-222 e Radioattività Ambientale nell'Impianto Idroelettrico di Pont Ventoux-Susa, Piemonte

Abstract not availableJRC-Joint Research Centr

Six years of Radiation Protection of Operators in the General Electric FDG-radiopharmaceutical facility at the Joint Research Centre of Ispra

Abstract The Joint Research Centre of Ispra, one of the research Sites belonging to the European Commission, Directorate General JRC, was created in the late '50s, in order to steer European research on nuclear industry. It currently hosts numerous nuclear facilities, some of which are maintained in operation, while others were shutdown in past years or are currently being decommissioned. Since 2003, a Radiopharmaceutical facility has been set up at the JRC Cyclotron Laboratory, in collaboration with General Electric Healthcare, for the production and commercialization of [18F]FDG. This Radiopharmaceutical Laboratory has been the first FDG production facility to be officially authorized by the Italian Health Ministry and has been operating since 2003 without any interruption. During these years, some upgrades in the capacity and maximum activity produced by the Lab have been performed. Two different beam lines and one irradiation vault have been devoted to FDG production in order to increase the production capability. The paper, thus, is a review of Radiation Protection activities performed in the Lab during its years of operation and in particular the distribution of the dose related to the activity and the daily personal dose trend, subdivided between FDG production and Quality Control (QC), will be shown and discussed. Further, a recent internal contamination dose assessment campaign will be presented and the results discussed.JRC.C.1-Nuclear Decommissionin